Lead Product(s) : ND081
Therapeutic Area : Gastroenterology
Study Phase : Preclinical
Sponsor : Kaken Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Numab and Kaken Collaborate On ND081 for Inflammatory Bowel Disease
Details : The collaboration aims to develop ND081, a potential first-in-class multi-specific antibody for the treatment of inflammatory bowel disease (IBD).
Product Name : ND081
Product Type : Other Large Molecule
Upfront Cash : $14.6 million
November 15, 2024
Lead Product(s) : ND081
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Sponsor : Kaken Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration